Inflammatory Bowel Diseases

Skip Navigation LinksHome > February 2014 - Volume 20 - Issue 2 > T-Cell Profiling and the Immunodiagnosis of Latent Tuberculo...
Inflammatory Bowel Diseases:
doi: 10.1097/01.MIB.0000438429.38423.62
Original Basic Science Articles

T-Cell Profiling and the Immunodiagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease

Arias-Guillén, Miguel MD*; Riestra, Sabino MD, PhD; de Francisco, Ruth MD; Palacios, Juan José MD, PhD; Belda, José MD, PhD§; Escalante, Patricio MD, MSc; Pérez-Martínez, Isabel MD; Molinos, Luis M. PhD; Garcia-Clemente, Marta MD, PhD*; Pando-Sandoval, Ana MD*; Rodrigo, Luis MD, PhD; Prieto, Amador MD; Martínez-Camblor, Pablo PhD**; Losada, Ana RN*; Casan, Pere MD, PhD*

Collapse Box


Background: Factors associated with performance of interferon-γ release assays (IGRA) and the tuberculin skin test (TST) in screening for latent tuberculosis infection in patients with inflammatory bowel diseases (IBD) are still poorly understood. The influence of peripheral T-cell subset counts on the results also remain unclear.

Methods: Prospective single-center study in 205 patients with IBD. Latent tuberculosis infection screening included a chest radiograph, TST (retest if negative), and 2 IGRAs: QuantiFERON-TB Gold In-Tube (QFT-GIT) and TSPOT-TB (TSPOT). T-cell subpopulations were determined by flow cytometry.

Results: Twenty-one (10.2%) patients had an abnormal chest radiograph, 55 (26.8%) had a positive TST, 16 (7.8%) had a positive QFT-GIT, and 25 (12.6%) had a positive TSPOT. TST positivity was lower in patients on ≥2 immunosuppressants compared with the controls (5-aminosalicylic acid treatment) (10.4% versus 38.2%, respectively) (P = 0.0057). No other drugs influenced TST or IGRA positivity. In patients on corticosteroid treatment, anti-TNF treatment, or ≥2 immunosuppressants, IGRAs detected 10 cases of latent tuberculosis infection not identified by TST. TSPOT and QFT-GIT increased yield by 56% and 22%, respectively. No significant differences in T-cell subpopulations were found between patients with positive or negative TST or TSPOT results. However, patients with positive QFT-GIT findings had more CD8+ T cells (mean, 883 ± 576 versus 484 ± 385 cells per microliter in patients with negative results) (P = 0.022).

Conclusions: IGRAs can improve TST-based screening in patients with IBD on immunosuppressive therapy. A low CD8+ count can affect QFT-GIT results. We suggest combining TSPOT and TST screening in patients with IBD on immunosuppressants.

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.